PTC Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary

• PTC Therapeutics, Inc. reported a quarterly adjusted loss of 62 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 20 cents. The mean expectation of sixteen analysts for the quarter was for earnings of 34 cents per share. Wall Street expected results to range from -90 cents to 97 cents per share.

• Revenue rose 69.6% to $357.81 million from a year ago; analysts expected $306.40 million.

• PTC Therapeutics, Inc.'s reported EPS for the quarter was a loss of 62 cents​.

• The company reported a quarterly loss of $51.69 million.

• PTC Therapeutics, Inc. shares had fallen by 2.7% this quarter and lost 17.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 30.9% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for PTC Therapeutics, Inc. is $98.00, about 34.2% above its last closing price of $64.46

This summary was machine generated from LSEG data October 29 at 10:21 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)